BioAtla shares rise 13.05% intraday after positive regulatory update on OPSCC drug development following FDA meeting.

BioAtla (NASDAQ:BCAB) surged 13.05% intraday after announcing a regulatory update on its clinical development plan for Ozuriftamab Vedotin in oropharyngeal squamous cell carcinoma (OPSCC) following a productive Type B (End of Phase 2) meeting with the FDA. The update, disclosed one hour prior to the price movement, highlights positive progress in the drug’s development timeline, signaling regulatory alignment and potential advancement toward later-stage trials. This development, coupled with recent encouraging data from Phase 2 trials at ASCO 2025 and a strategic focus on HPV-associated cancers, likely drove investor optimism. Other recent news, including a sell rating from Wall Street Zen and workforce reductions, were older and did not align with the intraday rally.